4-chloro-2-(2-chlorophenyl)pyridine | 1578241-95-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 4-chloro-2-(2-chlorophenyl)pyridine
• CAS: 1578241-95-8
• 化学式: C₁₁H₇Cl₂N
• 分子量: 224.089
• InChiKey: AKEPAKFPPZDRDA-UHFFFAOYSA-N

物化性质

• 沸点：
  310.1±27.0 °C(Predicted)
• 密度：
  1.304±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  12.9
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  2-氯苯基硼酸 、 4-氯吡啶盐酸盐 在 ferrous(II) sulfate heptahydrate 、 dipotassium peroxodisulfate 、 sodium hydroxide 作用下， 以 二氯甲烷 、 水 为溶剂， 反应 5.0h， 生成 4-chloro-2-(2-chlorophenyl)pyridine 、 4-Chloro-3-(2-chlorophenyl)pyridine
  参考文献：
  名称：

  FeSO4介导的杂芳烃与芳基硼酸直接芳基化及其合成应用的范围和限制

  摘要：

  已经开发了在 K2S2O8 存在下 FeSO4 介导的杂芳烃与芳基硼酸的直接芳基化。缓慢添加铁络合物的水溶液在 ary...

  DOI：

  10.1246/bcsj.20130166

文献信息

• Pyrazole compounds useful as protein kinase inhibitors
  申请人：VERTEX PHARMACEUTICALS INCORPORATED

  公开号：EP1698627A1

  公开（公告）日：2006-09-06

  This invention describes novel pyrazole compounds of formula II: wherein Ring C is selected from a phenyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, or 1,2,4-triazinyl ring, and R2, R2, Rx, and Ry are as described in the specification. Ring C has an ortho substituent and is optionally substituted in the non-ortho positions. R2 and R2 are optionally taken together with their intervening atoms to form a fused ring system, such as an indazole ring; and Rx and Ry are optionally taken together with their intervening atoms to form a fused ring system, such as a quinazoline ring. The compounds are useful as protein kinase inhibitors, especially as inhibitors of GSK-3, for treating diseases such as diabetes and Alzheimer's disease.

  本发明描述了式 II 的新型吡唑化合物：其中环 C 选自苯基、吡啶基、嘧啶基、哒嗪基、吡嗪基或 1，2，4-三嗪基环，R2、R2、Rx 和 Ry 如说明书所述。环 C 具有一个正交取代基，并可选择在非正交位置被取代。R2 和 R2 与它们之间的原子任选结合在一起形成一个融合环系统，如吲唑环；Rx 和 Ry 与它们之间的原子任选结合在一起形成一个融合环系统，如喹唑啉环。这些化合物可作为蛋白激酶抑制剂，尤其是 GSK-3 的抑制剂，用于治疗糖尿病和阿尔茨海默病等疾病。
• PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS
  申请人：VERTEX PHARMACEUTICALS INCORPORATED

  公开号：EP1317447A1

  公开（公告）日：2003-06-11
• TRIAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS
  申请人：VERTEX PHARMACEUTICALS INCORPORATED

  公开号：EP1318814A2

  公开（公告）日：2003-06-18
• [EN] TRIAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS<br/>[FR] COMPOSES DE TRIAZOLE, INHIBITEURS DE LA PROTEINE KINASE
  申请人：VERTEX PHARMA

  公开号：WO2002022602A2

  公开（公告）日：2002-03-21

  This invention describes novel triazole compounds of formula (IX): wherein Z1 is nitrogen or CR?9 and Z2¿ is nitrogen or CH, provided that at least one of Z?1 and Z2¿ is nitrogen; G is Ring C or Ring D; Ring C is selected from a phenyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, or 1,2,4-triazinyl ring, wherein said Ring C has one or two ortho substituents independently selected from -R1; Ring D is a 5-7 membered monocyclic ring or 8-10 membered bicyclic ring selected from aryl, heteroaryl, heterocyclyl or carbocyclyl; R?x and Ry¿ are independently selected from T-R?3, or Rx and Ry¿ are taken together with their intervening atoms to form a fused ring; R1, R3, and T are as described in the specification. The compounds are useful as protein kinase inhibitors, especially as inhibitors of GSK-3 and Aurora, for treating diseases such as diabetes, cancer, and Alzheimer's disease.
• [EN] PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS<br/>[FR] COMPOSES PYRAZOLE UTILES EN TANT QU'INHIBITEURS DE PROTEINE KINASE
  申请人：VERTEX PHARMA

  公开号：WO2002022607A1

  公开（公告）日：2002-03-21

  This invention describes novel pyrazole compounds of formula II:wherein Ring C is selected from a phenyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl, or 1, 2, 4-triazinyl ring, and R?2, R2, Rx, and Ry¿ are as described in the specification. Ring C has an ortho substituent and is optionally substituted in the non-ortho positions. R?2 and R2¿ are optionally taken together with their intervening atoms to form a fused ring system, such as an indazole ring; and R?x and Ry¿ are optionally taken together with their intervening atoms to form a fused ring system, such as a quinazoline ring. The compounds are useful as protein kinase inhibitors, especially as inhibitors of GSK-3, for treating diseases such as diabetes and Alzheimer's disease.